Bank of America Corp DE grew its holdings in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 52.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 300,356 shares of the company's stock after acquiring an additional 103,667 shares during the period. Bank of America Corp DE owned about 0.48% of Kodiak Sciences worth $11,450,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of KOD. Westfuller Advisors LLC bought a new position in shares of Kodiak Sciences in the 1st quarter worth about $26,000. V Square Quantitative Management LLC acquired a new position in Kodiak Sciences during the 1st quarter valued at about $26,000. EverSource Wealth Advisors LLC raised its holdings in Kodiak Sciences by 1,221.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company's stock worth $28,000 after purchasing an additional 916 shares in the last quarter. Headlands Technologies LLC lifted its holdings in shares of Kodiak Sciences by 256.4% in the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company's stock valued at $30,000 after buying an additional 5,815 shares during the period. Finally, KBC Group NV bought a new position in shares of Kodiak Sciences during the 1st quarter valued at about $39,000. Hedge funds and other institutional investors own 89.06% of the company's stock.
Kodiak Sciences Stock Down 3.8%
Shares of KOD stock opened at $38.33 on Friday. Kodiak Sciences Inc. has a 12-month low of $8.29 and a 12-month high of $47.84. The firm has a fifty day moving average of $39.90 and a 200-day moving average of $35.47. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -9.15 and a beta of 2.21.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.09). Research analysts expect that Kodiak Sciences Inc. will post -3.83 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on KOD. JPMorgan Chase & Co. lifted their price target on Kodiak Sciences from $56.00 to $66.00 and gave the stock an "overweight" rating in a research note on Monday, August 3rd. Wall Street Zen lowered Kodiak Sciences from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Kodiak Sciences in a research report on Friday, July 10th. HC Wainwright restated a "buy" rating and set a $58.00 target price on shares of Kodiak Sciences in a research note on Monday, August 17th. Finally, Chardan Capital upgraded Kodiak Sciences from a "neutral" rating to a "buy" rating and upped their target price for the company from $14.00 to $61.00 in a research note on Monday, May 11th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $48.14.
Check Out Our Latest Report on KOD
About Kodiak Sciences
(
Free Report)
Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.
The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.
Recommended Stories
Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KOD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
